Vir Biotechnology Inc [VIR] stock is trading at $5.23, up 17.79%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VIR shares have gain 19.95% over the last week, with a monthly amount drifted -0.38%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vir Biotechnology Inc [NASDAQ: VIR] stock has seen the most recent analyst activity on August 27, 2025, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $14 for it. Previously, JP Morgan downgraded its rating to Neutral on January 29, 2024, and dropped its price target to $9. On September 08, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $14 on the stock. JP Morgan upgraded its rating to a Overweight and decreased its price target to $34 on March 06, 2023. Goldman upgraded its rating to a Buy and raised its price target to $53 on February 21, 2023. Morgan Stanley upgraded its rating to Equal-Weight for this stock on January 27, 2023, and upped its price target to $30. In a note dated September 14, 2022, SVB Leerink initiated an Outperform rating and provided a target price of $40 on this stock.
Vir Biotechnology Inc [VIR] stock has fluctuated between $4.16 and $14.45 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Vir Biotechnology Inc [NASDAQ: VIR] shares were valued at $5.23 at the most recent close of the market. An investor can expect a potential return of 129.45% based on the average VIR price forecast.
Analyzing the VIR fundamentals
Vir Biotechnology Inc [NASDAQ:VIR] reported sales of 19.00M for the trailing twelve months, which represents a drop of -60.52%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -35.62%, Pretax Profit Margin comes in at -33.0%, and Net Profit Margin reading is -33.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.5 and Total Capital is -0.55. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.78 points at the first support level, and at 4.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.75, and for the 2nd resistance point, it is at 6.27.
Ratios To Look Out For
For context, Vir Biotechnology Inc’s Current Ratio is 7.01. Also, the Quick Ratio is 7.01, while the Cash Ratio stands at 2.85. Considering the valuation of this stock, the price to sales ratio is 38.24, the price to book ratio is 0.77.
Transactions by insiders
Recent insider trading involved SATO VICKI L, Director, that happened on Aug 01 ’25 when 22000.0 shares were sold. EVP and Chief Medical Officer, Eisner Mark completed a deal on Jul 15 ’25 to sell 6796.0 shares. Meanwhile, EVP and Chief Medical Officer Eisner Mark sold 3586.0 shares on Jul 17 ’25.
